|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-3-16
|
|
pubmed:abstractText |
In the LIPS (Lescol Intervention Prevention Study), fluvastatin 80 mg/day reduced the risk of major adverse cardiac events (MACE) by 22% versus placebo (p = 0.01) following successful first percutaneous coronary intervention (PCI) in patients with stable or unstable angina or silent ischemia. The cost-effectiveness of such therapy is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1060-0280
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
610-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15741421-Aged,
pubmed-meshheading:15741421-Angina, Unstable,
pubmed-meshheading:15741421-Atherectomy, Coronary,
pubmed-meshheading:15741421-Cost-Benefit Analysis,
pubmed-meshheading:15741421-Fatty Acids, Monounsaturated,
pubmed-meshheading:15741421-Humans,
pubmed-meshheading:15741421-Indoles,
pubmed-meshheading:15741421-Markov Chains,
pubmed-meshheading:15741421-Middle Aged,
pubmed-meshheading:15741421-Quality of Life,
pubmed-meshheading:15741421-Risk Reduction Behavior
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention.
|
|
pubmed:affiliation |
Policy Analysis Inc. (PAI), Brookline, MA 02245-7629, USA. tdelea@pai2.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
